Business - Globe24h

back to index contact: globe @ globe24h.com

We respect intellectual property rights and will take appropriate steps to protect these rights.
If you believe your copyright has been infringed on, please send us a message with the following information:
1. An identification of the copyrighted work that you claim has been infringed
2. A link to the material located on Globe24h.com that you claim is a copyright infringement
3. Information on how to contact you including your address, telephone number, and email address.
Please send your message to: copyright @ globe24h.com

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 16, 1995

CYTOGEN CORPORATION

(Exact name of registrant as specified in its charter)

  Delaware                          1-14879                  22-2322400
- --------------------------------------------------------------------------------
(State or other jurisdiction      (Commission              (IRS Employer
of incorporation)                 File Number)           Identification No.

600 College Road East, CN5308, Princeton, New Jersey 08540-5308
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 987-8200

This document consists of 5 pages.

Item 5. Other Events.

On October 16, 1995, Cytogen Corporation issued the attached press release.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(a) Financial Statements -- Not applicable.
(b) Pro Forma Financial Information -- Not applicable.
(c) Exhibits:

Exhibit No.                   Description                      Page
- -----------                   -----------                      ----

99                            Press release issued by Cytogen     5
                              Corporation on October 16, 1995.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CYTOGEN CORPORATION
(Registrant)

By: T. Jerome Madison

T. Jerome Madison Vice President, Chief Financial Officer and Secretary

Date: October 16, 1995

EXHIBIT INDEX

Exhibit No.
As provided                                             Page in
in Item 601                                             Sequentially
Exhibit Number    Description                           Numbered Copy
- --------------    -----------                           -------------

99                Press release issued by Cytogen             5


                  Corporation on October 16, 1995.

Exhibit 99

Pamela M. Murphy
CYTOGEN Corporation
609-987-8221

For Immediate Release

CYTOGEN STOCKHOLDERS APPROVE MERGER WITH CELLCOR

PRINCETON, N.J., October 16, 1995 -- CYTOGEN Corporation (NASDAQ:CYTO) announced that CYTOGEN stockholders voting on the issuance of CYTOGEN securities to acquire Cellcor Incorporated (OTC:CLTX) ("Cellcor") and to undertake a subscription offering to Cellcor stockholders, approved the transactions at a special meeting held today. A preliminary count indicated that of the 17.3 million outstanding shares voted, over 95% endorsed the proposal. Cellcor stockholders also voted to approve the merger at a separate special meeting held today. The closing of the merger will occur on or by October 19, 1995.

In conjunction with CYTOGEN's acquisition of Cellcor, the subscription offering was made to record holders of Cellcor common stock, as of the record date of August 17, 1995, to purchase for cash up to $23.5 million of CYTOGEN common stock at $3.89 per share. Hillman Medical Ventures and its affiliates, Cellcor's largest stockholder, purchased $11.5 million of the offering. Other shareholders of Cellcor purchased an additional $8.5 million of CYTOGEN common stock, raising a total of $20.0 million for CYTOGEN.

CYTOGEN's President and CEO, Thomas J. McKearn stated, "As we have said in the past, our strategy is to add complementary, late-stage products, technologies and services to CYTOGEN's existing portfolio. Cellcor has recently completed the patient accrual for its Phase III pivotal trial using autolymphocyte therapy (ALT) to treat metastatic kidney cancer patients. The acquisition of Cellcor with its focus in cancer, as well as in infectious diseases, complements and broadens our pipeline with a late-stage product and a proprietary technology."

ALT is a proprietary immunotherapy using a patient's own immune cells to treat cancer and certain infectious diseases. It is an outpatient non-toxic treatment that can be delivered to patients nationally from a central cell processing facility. ALT is the ex vivo activation of autologous T cells, which lead the immune system's response to foreign antigens such as cancer or infectious disease.

CYTOGEN is a biopharmaceutical company engaged in the marketing and development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary technologies to develop specific diagnostic imaging and therapeutic products.

Cellcor, Inc. is a biotechnology company engaged in the development of cellular therapies with initial application in the treatment of certain cancers and potential application in the areas of infectious disease.

###